This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group Search for Related Content PubMed PubMed Citation Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group, Social Bookmarking                         What's this?

Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension

Service de Néphrologie, Hôpital Civil, Strasbourg, France

Jacques Chanard

Service de Néphrologie, Hôpital Maison-Blanche, Reims, France

Bertrand Baumelou

Clinical Research Unit, Boehringer Ingelheim, Reims, France

French Collaborative Telmisartan Study Group

The effect on renal function and efficacy of the angiotensin II AT₁-receptor blocker (ARB), telmisartan, were compared with those of the angiotensin-converting enzyme inhibitor, enalapril, for the treatment of mild-to-moderate hypertension (diastolic blood pressure [DBP] 95—114 mmHg) in the presence of moderate renal failure (creatinine clearance [Ccr] 30—80 ml/minute). The study was multicentre, double-blind, double-dummy and active-controlled in design, with patients randomised in a 2:1 ratio to receive telmisartan or enalapril. After a two-week placebo run-in period, the 71 eligible patients received either telmisartan, 40 mg, or enalapril, 10 mg, once-daily for four weeks. Thereafter, doses were titrated to telmisartan 80 mg or enalapril 20 mg once-daily if supine trough DBP was still 90 mmHg. After a further four weeks, dose titration was again performed, as required, to telmisartan, 80 mg, or enalapril, 20 mg, or frusemide was given in addition if the double dose was already being administered. Mean Ccr decreases of 4.6% for telmisartan and 2.8% for enalapril were not clinically significant. Adverse events occurred in 12 (26.7%) telmisartan-treated patients and in 12 (46.2%) patients receiving enalapril. The mean reduction in supine trough DBP from baseline to the last available value was 12.5 mmHg for telmisartan, compared with 11.9 mmHg for enalapril. A full (reduction of 10 mmHg) or partial (reduction of 7—9 mmHg) response occurred in 78% of telmisartan patients and 65% of enalapril patients. In the enalapril group, 43% of patients required frusemide, compared with 29% of those in the telmisartan group. In conclusion, telmisartan lacks detrimental effect on renal function, is effective in the treatment of mild-to-moderate hypertension in patients with moderate renal failure, and is comparable to enalapril.

Key Words: telmisartan • renal safety • creatinine clearance • enalapril • hypertension

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 4, 246-254 (2001)
DOI: 10.3317/jraas.2001.039


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Barnett Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S132 - S135. [Abstract] [Full Text] [PDF]

				A.M. Sharma Renal involvement in hypertensive cardiovascular disease Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F12 - F18. [Abstract] [PDF]